Immix Biopharma Announces That All Four Relapsed/Refractory Al Amyloidosis MRDd-Negative Patients Presented At ASH 2025 Have Converted To Complete Response

–    Of first 20 patients, all four MRD-negative patients have converted to complete response (CR)  –

–   CR rate now 95% (19 of 20 patients)   –

–    All CRs reached within 1 year of follow-up post-dosing    –

–    No relapses to-date observed for patients who have reached CR    –

–    All subsequently enrolled patients for whom MRD results are available are MRD-negative at one month    –

–    Next NEXICART-2 Update Expected Late September, 2026    –